Company Overview of Merck Research Laboratories
Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders. The company was founded in 2004 and is based in Boston, Massachusetts. Merck Research Laboratories operates as a subsidiary of Merck & Co. Inc.
33 Avenue Louis Pasteur
Boston, MA 02115
Founded in 2004
Key Executives for Merck Research Laboratories
Senior Vice President and Franchise Head of Immunology, Respiratory, and Endocrine
Senior Vice President and Franchise Head of Diabetes and Obesity
Senior Vice President and Head of Neuroscience and Ophthalmology
Director of Human Resources
Compensation as of Fiscal Year 2016.
Merck Research Laboratories Key Developments
Merck Research Laboratories Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-13-2016 03:00 PM
Sep 10 16
Merck Research Laboratories Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-13-2016 03:00 PM. Venue: Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Liz Leveille, Executive Director, Business Development and Licensing.
Merck Research Laboratories Presents at 13th Annual BIO Asia International Conference 2016, Mar-16-2016 03:45 PM
Mar 11 16
Merck Research Laboratories Presents at 13th Annual BIO Asia International Conference 2016, Mar-16-2016 03:45 PM. Venue: Grand Hyatt, Tokyo, Japan. Speakers: Ji Li, Vice President, Business Development & Licensing.
ImmunoGen Enters into Clinical Research Collaboration with Merck
Feb 8 16
ImmunoGen, Inc. and Merck have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, Keytruda, or pembrolizumab, for the treatment of patients with FR¦Á-positive ovarian cancer. ImmunoGen is conducting a Phase Ib/II clinical trial, FORWARD II, that evaluates mirvetuximab soravtansine for FR¦Á-positive ovarian cancer used in doublet combination with other anticancer agents. The assessment of mirvetuximab soravtansine with Keytruda will be added to this trial, with Merck supplying the Keytruda. ImmunoGen expects this cohort to open for patient enrollment in the second half of 2016. The agreement is between ImmunoGen and Merck, through a subsidiary. The agreement includes a provision for potential expansion of the collaboration to include a subsequent Phase III clinical trial. ImmunoGen developed mirvetuximab soravtansine as a potential treatment for ovarian cancer and other FR¦Á-positive solid tumors. In early clinical testing, mirvetuximab soravtansine demonstrated notable activity when used as a single agent to treat platinum-resistant FR¦Á-positive ovarian cancer. ImmunoGen is assessing the ADC used as a single agent for pretreated FR¦Á-positive ovarian cancer in its Phase II trial, FORWARD I, which is intended to support an Accelerated Approval pathway. Mirvetuximab soravtansine is also now being assessed in separate combinations with pegylated liposomal doxorubicin (Doxil), bevacizumab (Avastin), and carboplatin in the Phase Ib/II trial, FORWARD II.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|